Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: From concept to application

Journal of Oncology

Volumn , Issue , 2012, Pages

  Amini, Afshin ^a   Masoumi Moghaddam, Samar ^a   Morris, David L ^a   Pourgholami, Mohammad H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CELECOXIB; CIGLITAZONE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INTEDANIB; MOTESANIB; PACLITAXEL; PAZOPANIB; PLACEBO; RAMUCIRUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; TOPOTECAN; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ASCITES; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL RESEARCH; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPEPSIA; DYSPHONIA; ESOPHAGUS FISTULA; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INTESTINE PERFORATION; KIDNEY DYSFUNCTION; LUNG HEMORRHAGE; NAUSEA; NEUTROPENIA; NONHUMAN; NOSE SEPTUM PERFORATION; OSTEOARTHRITIS; OVARY CANCER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; WEIGHT REDUCTION; WOUND HEALING;

EID: 81555220066     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/540791     Document Type: Review

References (128)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J., Cancer statistics, 2007 Ca: A Cancer Journal for Clinicians 2007 57 1 43 66 (Pubitemid 46148091)
2. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002 Ca: A Cancer Journal for Clinicians 2005 55 2 74 108 (Pubitemid 40372904)
3. Partridge E. E., Barnes M. N., Epithelial ovarian cancer: prevention, diagnosis, and treatment Ca: A Cancer Journal for Clinicians 1999 49 5 297 320
4. Coilinson F., Jayson G., New therapeutic agents in ovarian cancer Current Opinion in Obstetrics Gynecology 2009 21 1 44 53
5. Spannuth W. A., Sood A. K., Coleman R. L., Angiogenesis as a strategic target for ovarian cancer therapy Nature Clinical Practice Oncology 2008 5 4 194 204 (Pubitemid 351493679)
6. Kumaran G. C., Jayson G. C., Clamp A. R., Antiangiogenic drugs in ovarian cancer The British Journal of Cancer 2009 100 1 1 7
7. Crawford Y., Ferrara N., VEGF inhibition: insights from preclinical and clinical studies Cell and Tissue Research 2009 335 1 261 269
8. Papetti M., Herman I. M., Mechanisms of normal and tumor-derived angiogenesis The American Journal of PhysiologyCell Physiology 2002 282 5 C947 C970
9. Duhoux F. P., Machiels J. P., Antivascular therapy for epithelial ovarian cancer Journal of Oncology 2010 2010 9
10. Schumacher J. J., Dings R. P. M., Cosin J., Subramanian I. V., Auersperg N., Ramakrishnan S., Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells Cancer Research 2007 67 8 3683 3690 (Pubitemid 46762153)
11. Burger R. A., Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies Journal of Gynecologic Oncology 2010 21 1 3 11
12. Engels K., du Bois A., Harter P., Fisseler-Eckhoff A., Kommoss F., Stauber R., Kaufmann M., Nekljudova V., Loibl S., VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection Journal of Clinical Pathology 2009 62 5 448 454
13. Gadducci A., Ferrero A., Cosio S., Zola P., Viacava P., Dompé D., Fanelli G., Ravarino N., Motta M., Cristofani R., Genazzani A. R., Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable Anticancer Research 2006 26 5 B 3925 3932 (Pubitemid 44701480)
14. Sonmezer M., Gungor M., Ensari A., Orta F., Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor and vascular endothelial growth factor International Journal of Gynecological Cancer 2004 14 1 82 88 (Pubitemid 38280627)
15. Frumovitz M., Sood A. K., Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies Gynecologic Oncology 2007 104 3 768 778 (Pubitemid 46240274)
16. Kobold S., Hegewisch-Becker S., Oechsle K., Jordan K., Bokemeyer C., Atanackovic D., Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? The Oncologist 2009 14 12 1242 1251
17. Saaristo A., Karpanen T., Alitalo K., Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis Oncogene 2000 19 53 6122 6129 (Pubitemid 32059462)
18. Decaussin M., Sartelet H., Robert C., Moro D., Claraz C., Brambilla C., Brambilla E., Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival Journal of Pathology 1999 188 4 369 377 (Pubitemid 29327434)
19. Masood R., Cai J., Zheng T., Lynne Smith D., Hinton D. R., Gill P. S., Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors Blood 2001 98 6 1904 1913
20. Spannuth W. A., Nick A. M., Jennings N. B., Armaiz-Pena G. N., Mangala L. S., Danes C. G., Lin Y. G., Merritt W. M., Thaker P. H., Kamat A. A., Han L. Y., Tonra J. R., Coleman R. L., Ellis L. M., Sood A. K., Functional significance of VEGFR-2 on ovarian cancer cells International Journal of Cancer 2009 124 5 1045 1053
21. Kassim S. K., El-Salahy E. M., Fayed S. T., Helal S. A., Helal T., Azzam E. E. D., Khalifa A., Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients Clinical Biochemistry 2004 37 5 363 369 (Pubitemid 38490454)
22. Paley P. J., Staskus K. A., Gebhard K., Mohanraj D., Twiggs L. B., Carson L. F., Ramakrishnan S., Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer 1997 80 1 98 106 (Pubitemid 27270925)
23. Cooper B. C., Ritchie J. M., Broghammer C. L. W., Coffin J., Sorosky J. I., Buller R. E., Hendrix M. J. C., Sood A. K., Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clinical Cancer Research 2002 8 10 3193 3197 (Pubitemid 35155030)
24. Hefler L. A., Zeillinger R., Grimm C., Sood A. K., Cheng W. F., Gadducci A., Tempfer C. B., Reinthaller A., Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecologic Oncology 2006 103 2 512 517 (Pubitemid 44740099)
25. Zhang A., Meng L., Wang Q., Xi L., Chen G., Wang S., Zhou J., Lu Y., Ma D., Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2 Oncology Reports 2006 15 4 831 836
26. Byrne A. T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J. I., Yancopoulos G. D., Jaffe R. B., Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model Clinical Cancer Research 2003 9 15 5721 5728 (Pubitemid 37499496)
27. Goodheart M. J., Ritchie J. M., Rose S. L., Fruehauf J. P., DeYoung B. R., Buller R. E., The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer Clinical Cancer Research 2005 11 10 3733 3742 (Pubitemid 40685590)
28. Hefler L. A., Mustea A., Knsgen D., Concin N., Tanner B., Strick R., Heinze G., Grimm C., Schuster E., Tempfer C., Reinthaller A., Zeillinger R., Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer Clinical Cancer Research 2007 13 3 898 901 (Pubitemid 46340365)
29. Shen G. H., Ghazizadeh M., Kawanami O., Shimizu H., Jin E., Araki T., Sugisaki Y., Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma The British Journal of Cancer 2000 83 2 196 203 (Pubitemid 30411717)
30. Ferrara N., Kerbel R. S., Angiogenesis as a therapeutic target Nature 2005 438 7070 967 974 (Pubitemid 43093963)
31. Osada R., Horiuchi A., Kikuchi N., Ohira S., Ota M., Katsuyama Y., Konishi I., Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas Human Pathology 2006 37 11 1414 1425 (Pubitemid 44584330)
32. Gerber H. P., Ferrara N., Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Research 2005 65 3 671 680 (Pubitemid 40216420)
33. Barrena Medel N. I., Wright J. D., Herzog T. J., Targeted therapies in epithelial ovarian cancer Journal of Oncology 2010 2010 9
34. Mesiano S., Ferrara N., Jaffe R. B., Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization The American Journal of Pathology 1998 153 4 1249 1256 (Pubitemid 28465848)
35. Hu L., Hofmann J., Zaloudek C., Ferrara N., Hamilton T., Jaffe R. B., Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer The American Journal of Pathology 2002 161 5 1917 1924 (Pubitemid 35265548)
36. Mabuchi S., Terai Y., Morishige K., Tanabe-Kimura A., Sasaki H., Kanemura M., Tsunetoh S., Tanaka Y., Sakata M., Burger R. A., Kimura T., Ohmichi M., Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model Clinical Cancer Research 2008 14 23 7781 7789
37. Burger R. A., Sill M. W., Monk B. J., Greer B. E., Sorosky J. I., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study Journal of Clinical Oncology 2007 25 33 5165 5171 (Pubitemid 350237599)
38. Cannistra S. A., Matulonis U. A., Penson R. T., Hambleton J., Dupont J., Mackey H., Douglas J., Burger R. A., Armstrong D., Wenham R., McGuire W., Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer Journal of Clinical Oncology 2007 25 33 5180 5186 (Pubitemid 350232248)
39. Micha J. P., Goldstein B. H., Rettenmaier M. A., Genesen M., Graham C., Bader K., Lopez K. L., Nickle M., Brown J. V., A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer International Journal of Gynecological Cancer 2007 17 4 771 776 (Pubitemid 47063333)
40. Garcia A. A., Hirte H., Fleming G., Yang D., Tsao-Wei D. D., Roman L., Groshen S., Swenson S., Markland F., Gandara D., Scudder S., Morgan R., Chen H., Lenz H. J., Oza A. M., Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia Journal of Clinical Oncology 2008 26 1 76 82
41. Penson R. T., Dizon D. S., Cannistra S. A., Roche M. R., Krasner C. N., Berlin S. T., Horowitz N. S., DiSilvestro P. A., Matulonis U. A., Lee H., King M. A., Campos S. M., Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors Journal of Clinical Oncology 2010 28 1 154 159
42. Monk B. J., Choi D. C., Pugmire G., Burger R. A., Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer Gynecologic Oncology 2005 96 3 902 905 (Pubitemid 40255525)
43. Wright J. D., Hagemann A., Rader J. S., Viviano D., Gibb R. K., Norris L., Mutch D. G., Powell M. A., Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 2006 107 1 83 89 (Pubitemid 43939034)
44. Richardson D. L., Backes F. J., Seamon L. G., Zanagnolo V., O'Malley D. M., Cohn D. E., Fowler J. M., Copeland L. J., Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer Gynecologic Oncology 2008 111 3 461 466
45. Chura J. C., Van Iseghem K., Downs L. S. Jr., Carson L. F., Judson P. L., Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Gynecologic Oncology 2007 107 2 326 330 (Pubitemid 47575735)
46. O'Malley D. M., Richardson D. L., Rheaume P. S., Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer Gynecologic Oncology 2011 121 2 269 272
47. Burger R. A., Brady M. F., Bookman M. A., Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study Journal of Clinical Oncology 2010 28 18 LBA1
48. Perren T., Swart A. M., Pfisterer J., ICON7: a phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer Proceedings of the European Society for Medical Oncology (ESMO) Congress April 2011 Milan, Italy ICON7. http://www.ctu.mrc.ac.uk/icon7/ contentpages/documents/ICON720ESMO20Presidential20Presentation.pdf
49. Reck M., Examining the safety profile of angiogenesis inhibitors: implications for clinical practice Targeted Oncology 2010 5 4 257 2567
50. Hapani S., Sher A., Chu D., Wu S., Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis Oncology 2010 79 1-2 27 38
51. Ranpura V., Hapani S., Wu S., Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis Journal of the American Medical Association 2011 305 5 487 494
52. Hu L., Hofmann J., Holash J., Yancopoulos G. D., Sood A. K., Jaffe R. B., Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model Clinical Cancer Research 2005 11 19 I 6966 6971 (Pubitemid 41428755)
53. Tew W. P., Colombo N., Ray-Coquard I., VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study Journal of Clinical Oncology 2007 25 18 5508
54. Colombo N., Mangili G., Mammoliti S., Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study Journal of Clinical Oncology 2008 26 15 14598
55. Krupitskaya Y., Wakelee H. A., Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer Current Opinion in Investigational Drugs 2009 10 6 597 605
56. Spratlin J. L., Mulder K. E., MacKey J. R., Ramucirumab (IMC-1121B): a novel attack on angiogenesis Future Oncology 2010 6 7 1085 1094
57. NCT00721162, Study of ramucirumab in ovarian cancer 2011. http://clinicaltrials.gov/ct2/show/study/NCT00721162/
58. Spratlin J. L., Cohen R. B., Eadens M., Gore L., Camidge D. R., Diab S., Leong S., O'Bryant C., Chow L. Q. M., Serkova N. J., Meropol N. J., Lewis N. L., Chiorean E. G., Fox F., Youssoufian H., Rowinsky E. K., Eckhardt S. G., Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 Journal of Clinical Oncology 2010 28 5 780 787
59. Wedge S. R., Kendrew J., Hennequin L. F., Valentine P. J., Barry S. T., Brave S. R., Smith N. R., James N. H., Dukes M., Curwen J. O., Chester R., Jackson J. A., Boffey S. J., Kilburn L. L., Barnett S., Richmond G. H. P., Wadsworth P. F., Walker M., Bigley A. L., Taylor S. T., Cooper L., Beck S., Jrgensmeier J. M., Ogilvie D. J., AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Research 2005 65 10 4389 4400 (Pubitemid 40775678)
60. Matulonis U. A., Berlin S., Ivy P., Tyburski K., Krasner C., Zarwan C., Berkenblit A., Campos S., Horowitz N., Cannistra S. A., Lee H., Lee J., Roche M., Hill M., Whalen C., Sullivan L., Tran C., Humphreys B. D., Penson R. T., Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer Journal of Clinical Oncology 2009 27 33 5601 5606
61. Hirte H. W., Vidal L., Fleming G. F., A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial Journal of Clinical Oncology 2008 26 15 5521
62. NCT00275028, AZD2171 in treating patients with recurrent ovarian, peritoneal, or fallopian tube cancer 2011. http://clinicaltrial.gov/ct2/show/ NCT00275028/
63. NCT00278343, AZD2171 in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer 2011. http://clinicaltrial.gov/ct2/show/NCT00278343/
64. NCT00544973, Carboplatin and paclitaxel with or without cediranib in treating women with relapsed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/study/ NCT00544973/
65. Matulonis U. A., Berlin S. T., Krasner C. N., Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer Journal of Clinical Oncology 2008 26 15 5501
66. Fong T. A., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K. P., McMahon G., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Research 1999 59 1 99 106 (Pubitemid 29062964)
67. Holtz D. O., Krafty R. T., Mohamed-Hadley A., Zhang L., Alagkiozidis I., Leiby B., Guo W., Gimotty P. A., Coukos G., Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer Journal of Translational Medicine 2008 6, article 2
68. NCT00006155, SU5416 and carboplatin to treat ovarian cancer 2011. http://clinicaltrials.gov/ct2/show/NCT00006155/
69. Bauerschlag D. O., Schem C., Tiwari S., Egberts J. H., Weigel M. T., Kalthoff H., Jonat W., Maass N., Meinhold-Heerlein I., Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice Anticancer Research 2010 30 9 3355 3360
70. Rauh-Hain J. A., Penson R. T., Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma International Journal of Gynecological Cancer 2008 18 5 934 936
71. NCT00543049, Randomized multicenter trial with SU11248 evaluating dosage,tolerability,toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor 2011. http://clinicaltrials.gov/ct2/show/NCT00543049/
72. NCT00768144, Sunitinib in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma 2011. http://clinicaltrials.gov/ct2/show/ NCT00768144/
73. NCT00979992, Sunitinib malate in treating patients with persistent or recurrent clear cell ovarian cancer 2011. http://clinicaltrials.gov/ct2/show/ NCT00979992/
74. Biagi J. J., Oza A. M., Grimshaw R., A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaNCIC CTG IND 185 Journal of Clinical Oncology 2008 26 15 5522
75. Eichholz A., Merchant S., Gaya A. M., Anti-angiogenesis therapies: their potential in cancer management Journal of OncoTargets and Therapy 2010 3 69 82
76. Matsumura N., Mandai M., Okamoto T., Yamaguchi K., Yamamura S., Oura T., Baba T., Hamanishi J., Kang H. S., Matsui S., Mori S., Murphy S. K., Konishi I., Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling Cancer Science 2010 101 12 2658 2663
77. DeGrendele H., Chu E., Marshall J., Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors Clinical Colorectal Cancer 2003 3 1 16 18 (Pubitemid 37220783)
78. Matei D., Sill M. W., Lankes H. A., Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial Journal of Clinical Oncology 2010 29 1 69 75
79. Lee J. M., Sarosy G. A., Annunziata C. M., Azad N., Minasian L., Kotz H., Squires J., Houston N., Kohn E. C., Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity The British Journal of Cancer 2010 102 3 495 499
80. NCT00390611, Paclitaxel and carboplatin with or without sorafenib in the first-line treatment of patients with ovarian cancer 2011. http:// clinicaltrials.gov/ct2/show/NCT00390611/
81. NCT00791778, Comparison of nexavar/placebo as maintenance therapy for patients with advanced ovarian or primary peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/NCT00791778/
82. NCT00096200, BAY 43-9006 plus paclitaxel/carboplatin in women with GYN tumors 2011. http://clinicaltrials.gov/ct2/show/NCT00096200/
83. NCT01047891, Efficacy and safety study of sorafenib with topotecan in patients with platinum-resistant recurrent ovarian cancer (TRIAS 2009) 2011. http://clinicaltrials.gov/ct2/show/NCT01047891/
84. NCT00436215, Sorafenib and bevacizumab to treat ovarian, fallopian and peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/NCT00436215/
85. NCT00096395, Sorafenib and gemcitabine in treating patients with recurrent or refractory ovarian cancer or primary peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/NCT00096395/
86. Schroder W., Witteveen E., Abadie S., A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to IV epithelial ovarian cancer Journal of Clinical Oncology 2005 23 16 5042
87. Wedge S. R., Ogilvie D. J., Dukes M., Kendrew J., Chester R., Jackson J. A., Boffey S. J., Valentine P. J., Curwen J. O., Musgrove H. L., Graham G. A., Hughes G. D., Thomas A. P., Stokes E. S. E., Curry B., Richmond G. H. P., Wadsworth P. F., Bigley A. L., Hennequin L. F., ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Research 2002 62 16 4645 4655
88. Annunziata C. M., Walker A. J., Minasian L., Yu M., Kotz H., Wood B. J., Calvo K., Choyke P., Kimm D., Steinberg S. M., Kohn E. C., Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2 Clinical Cancer Research 2010 16 2 664 672
89. Ledermann J. A., Raja F. A., Targeted trials in ovarian cancer Gynecologic Oncology 2010 119 1 151 156
90. Morabito A., Piccirillo M. C., Falasconi F., De Feo G., Del Giudice A., Bryce J., Di Maio M., De Maio E., Normanno N., Perrone F., Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions The Oncologist 2009 14 4 378 390
91. Hilberg F., Roth G. J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Quant J., Heckel A., Rettig W. J., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Research 2008 68 12 4774 4782
92. Ledermann J. A., Rustin G. J., Hackshaw A., A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC) Journal of Clinical Oncology 2009 27 15S 5501
93. NCT01015118, BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer 2011. http:// clinicaltrials.gov/ct2/show/NCT01015118/
94. Thaker P. H., Yazici S., Nilsson M. B., Yokoi K., Tsan R. Z., He J., Kim S. J., Fidler I. J., Sood A. K., Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors Clinical Cancer Research 2005 11 13 4923 4933 (Pubitemid 41557213)
95. Kamat A. A., Kim T. J., Landen C. N., Lu C., Han L. Y., Lin Y. G., Merritt W. M., Thaker P. H., Gershenson D. M., Bischoff F. Z., Heymach J. V., Jaffe R. B., Coleman R. L., Sood A. K., Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer Cancer Research 2007 67 1 281 288 (Pubitemid 46142786)
96. Hamberg P., Verweij J., Sleijfer S., (Pre-)Clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor The Oncologist 2010 15 6 539 547
97. Merritt W. M., Nick A. M., Carroll A. R., Lu C., Matsuo K., Dumble M., Jennings N., Zhang S., Lin Y. G., Spannuth W. A., Kamat A. A., Stone R. L., Shahzad M. M. K., Coleman R. L., Kumar R., Sood A. K., Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer Molecular Cancer Therapeutics 2010 9 4 985 995
98. Campos S. M., Ghosh S., A current review of targeted therapeutics for ovarian cancer Journal of Oncology 2010 2010 11
99. NCT00866697, Efficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/NCT00866697/
100. NCT01035658, Study of pazopanib and doxil in patients with advanced relapsed platinum-sensitive or platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma 2011. http://clinicaltrials.gov/ct2/show/ NCT01035658/
101. NCT01227928, Efficacy and safety of pazopanib monotherapy after first-line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/NCT01227928/
102. NCT01238770, A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer 2011. http://clinicaltrials.gov/ct2/show/NCT01238770/
103. NCT01262014, Clinical trial investigating pazopanib in patients with platinum-resistant advanced ovarian cancer 2011. http://clinicaltrials.gov/ct2/ show/NCT01262014/
104. Polverino A., Coxon A., Starnes C., Diaz Z., DeMelfi T., Wang L., Bready J., Estrada J., Cattley R., Kaufman S., Chen D., Gan Y., Kumar G., Meyer J., Neervannan S., Alva G., Talvenheimo J., Montestruque S., Tasker A., Patel V., Radinsky R., Kendall R., AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Research 2006 66 17 8715 8721 (Pubitemid 44449188)
105. NCT00574951, AMG 706 in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/NCT00574951/
106. Lenz W., Pfeiffer R. A., Kosenow W., Hayman D. J., Thalidomide and congenital abnormalities The Lancet 1962 279 7219 45 46
107. Mcbride W. G., Thalidomide and congenital abnormalities The Lancet 1961 278 7216 1358
108. Mujagic H., Chabner B. A., Mujagi Z., Mechanisms of action and potential therapeutic uses of thalidomide Croatian Medical Journal 2002 43 3 274 285 (Pubitemid 34665765)
109. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085 (Pubitemid 24139577)
110. Hurteau J. A., Brady M. F., Darcy K. M., McGuire W. P., Edmonds P., Pearl M. L., Ivanov I., Tewari K. S., Mannel R. S., Zanotti K., Benbrook D. M., Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group Study Gynecologic Oncology 2010 119 3 444 450
111. Risinger A. L., Giles F. J., Mooberry S. L., Microtubule dynamics as a target in oncology Cancer Treatment Reviews 2009 35 3 255 261
112. Carbonaro M., O'Brate A., Giannakakou P., Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression The Journal of Cell Biology 2011 192 1 83 99
113. Pourgholami M. H., Khachigian L. M., Fahmy R. G., Badar S., Wang L., Chu S. W. L., Morris D. L., Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis Biochemical and Biophysical Research Communications 2010 397 4 729 734
114. Pourgholami M. H., Szwajcer M., Chin M., Liauw W., Seef J., Galettis P., Morris D. L., Links M., Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer Cancer Chemotherapy and Pharmacology 2010 65 3 597 605
115. Pourgholami M. H., Cai Z. Y., Lu Y., Wang L., Morris D. L., Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice Clinical Cancer Research 2006 12 6 1928 1935
116. Pourgholami M. H., Cai Z. Y., Badar S., Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole BMC Cancer 2010 10 143
117. Pourgholami M. H., Cai Z. Y., Wang L., Badar S., Links M., Morris D. L., Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole Cancer Investigation 2009 27 2 171 177
118. Legge F., Salutari V., Paglia A., Phase II study on the combination carboplatin-celecoxib in heavily pre-treated recurrent ovarian carcinoma patients Journal of Clinical Oncology 2006 24 18 15009
119. NCT00538031, Cyclophosphamide with or without celecoxib in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer 2011. http://clinicaltrials.gov/ct2/show/NCT00538031/
120. Azam F., Mehta S., Harris A. L., Mechanisms of resistance to antiangiogenesis therapy European Journal of Cancer 2010 46 8 1323 1332
121. Hirte H. W., Novel developments in angiogenesis cancer therapy Current Oncology 2009 16 3 50 54
122. Ebos J. M. L., Lee C. R., Cruz-Munoz W., Bjarnason G. A., Christensen J. G., Kerbel R. S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 2009 15 3 232 239
123. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vials F., Inoue M., Bergers G., Hanahan D., Casanovas O., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 2009 15 3 220 231
124. Loges S., Mazzone M., Hohensinner P., Carmeliet P., Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 2009 15 3 167 170
125. Cohn D. E., Kim K. H., Resnick K. E., At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis Journal of Clinical Oncology 2011 29 10 1247 1251
126. Banerjee S., Gore M., The future of targeted therapies in ovarian cancer The Oncologist 2009 14 7 706 716
127. Thigpen T., Stuart G., du Bois A., Friedlander M., Fujiwara K., Guastalla J. P., Kaye S., Kitchener H., Kristensen G., Mannel R., Meier W., Miller B., Poveda A., Provencher D., Stehman F., Vergote I., Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens Annals of Oncology 2005 16 8 viii13 viii19
128. Markman M., The promise and perils of targeted therapy of advanced ovarian cancer Oncology 2008 74 1-2 1 6 (Pubitemid 351915002)